Viking Therapeutics - Press Releases http://ir.vikingtherapeutics.com/ Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update http://ir.vikingtherapeutics.com/2017-11-08-Viking-Therapeutics-Reports-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update - VK5211 Phase 2 hip fracture study nearing completion, data expected 4Q17 Wed, 08 Nov 2017 16:05:00 -0500 http://ir.vikingtherapeutics.com/2017-11-08-Viking-Therapeutics-Reports-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 http://ir.vikingtherapeutics.com/2017-11-01-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2017-on-November-8-2017 Conference Call Scheduled for Wednesday, November 8 at 4:30p.m. Eastern Time Wed, 01 Nov 2017 07:30:00 -0400 http://ir.vikingtherapeutics.com/2017-11-01-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2017-on-November-8-2017 Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) http://ir.vikingtherapeutics.com/2017-10-24-Viking-Therapeutics-Presents-Results-from-In-Vivo-Study-of-VK2809-in-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH-at-the-Annual-Meeting-of-the-American-Association-for-the-Study-of-Liver-Diseases-AASLD Statistically Significant Reductions Observed in Fibrosis, Steatosis and NAS Score Following Eight Weeks of VK2809 Treatment vs Vehicle Controls Tue, 24 Oct 2017 07:05:00 -0400 http://ir.vikingtherapeutics.com/2017-10-24-Viking-Therapeutics-Presents-Results-from-In-Vivo-Study-of-VK2809-in-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH-at-the-Annual-Meeting-of-the-American-Association-for-the-Study-of-Liver-Diseases-AASLD Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association http://ir.vikingtherapeutics.com/2017-10-23-Viking-Therapeutics-Presents-Results-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-ALD-at-the-87th-Annual-Meeting-of-the-American-Thyroid-Association Results Demonstrate Significant Reductions in Plasma and Tissue Very Long Chain Fatty Acids, Potential Biomarkers of Therapeutic Effects, Following Treatment With VK0214 Mon, 23 Oct 2017 07:05:00 -0400 http://ir.vikingtherapeutics.com/2017-10-23-Viking-Therapeutics-Presents-Results-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-ALD-at-the-87th-Annual-Meeting-of-the-American-Thyroid-Association Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) http://ir.vikingtherapeutics.com/2017-10-04-Viking-Therapeutics-Announces-Top-Line-Results-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-ALD Treatment with VK0214 led to Significant Reductions in Plasma and Tissue Levels of Very Long Chain Fatty Acids (VLCFAs) Wed, 04 Oct 2017 07:05:00 -0400 http://ir.vikingtherapeutics.com/2017-10-04-Viking-Therapeutics-Announces-Top-Line-Results-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-ALD